Literature DB >> 26085907

Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.

Matthew M Yeh1, Raymond S Yeung1, Smith Apisarnthanarax1, Renuka Bhattacharya1, Carlos Cuevas1, William P Harris1, Tony Lim Kiat Hon1, Siddharth A Padia1, James O Park1, Kevin M Riggle1, Sayed S Daoud1.   

Abstract

Hepatocellular carcinoma (HCC) is the most rapidly increasing type of cancer in the United States. HCC is a highly malignant cancer, accounting for at least 14000 deaths in the United States annually, and it ranks third as a cause of cancer mortality in men. One major difficulty is that most patients with HCC are diagnosed when the disease is already at an advanced stage, and the cancer cannot be surgically removed. Furthermore, because almost all patients have cirrhosis, neither chemotherapy nor major resections are well tolerated. Clearly there is need of a multidisciplinary approach for the management of HCC. For example, there is a need for better understanding of the fundamental etiologic mechanisms that are involved in hepatocarcinogenesis, which could lead to the development of successful preventive and therapeutic modalities. It is also essential to define the cellular and molecular bases for malignant transformation of hepatocytes. Such knowledge would: (1) greatly facilitate the identification of patients at risk; (2) prompt efforts to decrease risk factors; and (3) improve surveillance and early diagnosis through diagnostic imaging modalities. Possible benefits extend also to the clinical management of this disease. Because there are many factors involved in pathogenesis of HCC, this paper reviews a multidisciplinary perspective of recent advances in basic and clinical understanding of HCC that include: molecular hepatocarcinogenesis, non-invasive diagnostics modalities, diagnostic pathology, surgical modality, transplantation, local therapy and oncological/target therapeutics.

Entities:  

Keywords:  Diagnostic imaging; Diagnostic pathology; Epigenetic alterations; Genetic alterations; Hepatocellular carcinoma; Liver resection; Liver transplantation; Locoregional therapy; Sorafenib; Surgical modality

Year:  2015        PMID: 26085907      PMCID: PMC4462686          DOI: 10.4254/wjh.v7.i11.1460

Source DB:  PubMed          Journal:  World J Hepatol


  177 in total

1.  Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.

Authors:  Daniel B Brown; Jennifer E Gould; Debra A Gervais; S Nahum Goldberg; Ravi Murthy; Steven F Millward; William S Rilling; Jean-Francois S Geschwind; Riad Salem; Suresh Vedantham; John F Cardella; Michael C Soulen
Journal:  J Vasc Interv Radiol       Date:  2009-07       Impact factor: 3.464

2.  New agents on the horizon in hepatocellular carcinoma.

Authors:  Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

3.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

4.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

Review 5.  Portal vein embolization for hepatocellular carcinoma.

Authors:  Junichi Shindoh; Ching-Wei D Tzeng; Jean-Nicolas Vauthey
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

6.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Authors:  Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

7.  The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.

Authors:  Lu-Nan Qi; Tao Bai; Zu-Shun Chen; Fei-Xiang Wu; Yuan-Yuan Chen; Bang- De Xiang; Tao Peng; Ze-Guang Han; Le-Qun Li
Journal:  Liver Int       Date:  2014-01-27       Impact factor: 5.828

8.  Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma.

Authors:  Zhi-Yong Xu; Shi-Xiong Liang; Ji Zhu; Xiao-Dong Zhu; Jian-Dong Zhao; Hai-Jie Lu; Yun-Li Yang; Long Chen; An-Yu Wang; Xiao-Long Fu; Guo-Liang Jiang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-20       Impact factor: 7.038

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  7 in total

1.  Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma.

Authors:  Guangfu Li; Kevin F Staveley-O'Carroll; Eric T Kimchi
Journal:  J Clin Trials       Date:  2016-04-05

2.  Dual-balloon infusion microcatheter for selective drug-eluting bead transarterial chemoembolization: initial feasibility study.

Authors:  Wayne L Monsky; Siddharth A Padia; Andrew Hal Hardy
Journal:  Diagn Interv Radiol       Date:  2017 Nov-Dec       Impact factor: 2.630

3.  Circ_0015756 Aggravates Hepatocellular Carcinoma Development by Regulating FGFR1 via Sponging miR-610.

Authors:  Weisheng Guo; Lin Zhao; Guangya Wei; Peng Liu; Yu Zhang; Liran Fu
Journal:  Cancer Manag Res       Date:  2020-08-18       Impact factor: 3.989

4.  Comparison of Hepatocellular Carcinoma in Hispanic and Non-Hispanic Patients.

Authors:  Joseph Asemota; Olubunmi Oladunjoye; Atinuke Babalola; Ugonna Nwosu; Po-Hong S Liu; Adeolu O Oladunjoye; Nelsy Castro-Webb; Rebecca A Miksad
Journal:  Cureus       Date:  2021-05-07

5.  Genomic variants link to hepatitis C racial disparities.

Authors:  Matthew M Yeh; Sarag Boukhar; Benjamin Roberts; Nairanjana Dasgupta; Sayed S Daoud
Journal:  Oncotarget       Date:  2017-08-01

6.  Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older.

Authors:  Jong Man Kim; Jinsoo Rhu; Sang Yun Ha; Gyu-Seong Choi; Choon Hyuck David Kwon; Gaabsoo Kim; Jae-Won Joh
Journal:  Ann Surg Treat Res       Date:  2021-10-29       Impact factor: 1.859

7.  Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer.

Authors:  Xiaoqiang Qi; Samuel Sk Lam; Dai Liu; Dae Young Kim; Lixin Ma; Lu Alleruzzo; Wei Chen; Tomas Hode; Carolyn J Henry; Jussuf Kaifi; Eric T Kimchi; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  J Clin Cell Immunol       Date:  2016-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.